Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

India equity markets end in red
Wed, 10 Jul Closing

Indian equity markets opened the day on a weak note and dropped in the late afternoon session on concerns over growth recovery in China after exports in the world's second-biggest economy fell for the first time in 17 months. While the BSE-Sensex closed lower by 145 points, the NSE-Nifty closed lower by 42 points. Both the BSE Mid Cap and the BSE Small Cap closed on a negative note. Oil and Gas and Auto stocks were the biggest losers.

As regards global markets, Asian indices closed in the green. European indices have opened in the red. The rupee was trading at Rs 60.35 to the dollar at the time of writing.

According to a leading financial daily, Tata Steel has reported a 26% jump in sales at 2.005 million tonnes (MT) in the first quarter of this fiscal ended June 30. The company had sold 1.585 MT during the April-June quarter of previous fiscal and 2.279 MT during the January- March, 2013 period. Production of saleable steel of the company also rose by 23% to touch 2.145 MT during the April-June period of the current fiscal from 1.740 MT a year ago. Tata Steel had produced 2.263 MT saleable steel during January-March 2013 quarter. Total hot metal production of the company was higher by 20% to 2.464 MT during the reporting quarter compared to 2.053 MT a year earlier. Crude steel production was also accordingly up by 22% to 2.223 MT during the April-June quarter of the current fiscal compared to 1.817 MT a year earlier.

According to a leading financial daily, Dr Reddy's has said that it will focus on fixing its European operations and strengthening its local business, the two major markets where it has underperformed. Dr Reddy's European sales declined in FY13 on account of its struggling German unit Betapharm Arzneimittel GmbH, which contributes about 70-75% of revenue in Europe. Dr Reddy's bought Betapharm, the fourth largest German generic drug marketing firm in February 2006 but a dramatic shift of policy in Germany to source medicines from the lowest-cost vendor through a tender-based model has hurt the company. As part of the new turnaround strategy for Germany, Dr Reddy's will launch products outside the scope of tenders and plans to adopt a selective approach of picking its product portfolio.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "India equity markets end in red". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.